Cytokine Therapy Combined with Nanomaterials Participates in Cancer Immunotherapy

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2022 Dec 23

PMID 36559100

Authors

Heping Lian

Shuang Ma

Duoyi Zhao

Wei Zhao

Yan Cui

Yingqi Hua

Zhiyu Zhang

Affiliations

Soon will be listed here.

Abstract

Immunotherapy has gradually become an emerging treatment modality for tumors after surgery, radiotherapy, and chemotherapy. Cytokine therapy is a promising treatment for cancer immunotherapy. Currently, there are many preclinical theoretical bases to support this treatment strategy and a variety of cytokines in clinical trials. When cytokines were applied to tumor immunotherapy, it was found that the efficacy was not satisfactory. As research on tumor immunity has deepened, the role of cytokines in the tumor microenvironment has been further explored. Meanwhile, the study of nanomaterials in drug delivery has been fully developed in the past 20 years. Researchers have begun to think about the possibility of combining cytokine therapy with nanomaterials. Herein, we briefly review various nano-delivery systems that can directly deliver cytokines or regulate the expression of cytokines in tumor cells for cancer immunotherapy. We further discussed the feasibility of the combination of various therapies. We looked forward to the main challenges, opportunities, and prospects of tumor immunotherapy with multiple cytokines and a nano-delivery system.

Citing Articles

Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges.

Wang M, Yu F, Zhang Y Mol Cancer. 2025; 24(1):26.

PMID: 39827147 PMC: 11748575. DOI: 10.1186/s12943-024-02214-5.

CAR T Cell Nanosymbionts: Revealing the Boundless Potential of a New Dyad.

Baena J, Perez L, Toro-Pedroza A, Kitawaki T, Loukanov A Int J Mol Sci. 2024; 25(23).

PMID: 39684867 PMC: 11642191. DOI: 10.3390/ijms252313157.

Nanomedicine for cancer patient-centered care.

Sorrentino C, Ciummo S, Fieni C, Di Carlo E MedComm (2020). 2024; 5(11):e767.

PMID: 39434967 PMC: 11491554. DOI: 10.1002/mco2.767.

References

Castro F, Pinto M, Silva A, Pereira C, Teixeira G, Gomez-Lazaro M . Pro-inflammatory chitosan/poly(γ-glutamic acid) nanoparticles modulate human antigen-presenting cells phenotype and revert their pro-invasive capacity. Acta Biomater. 2017; 63:96-109. DOI: 10.1016/j.actbio.2017.09.016. View

Aulitzky W, Gastl G, Tilg H, Troppmair J, Leiter E, Geissler D . [Interferon-alpha in the treatment of hematologic neoplasms]. Wien Med Wochenschr. 1986; 136(7-8):172-81. View

Mcdermott D, Regan M, Clark J, Flaherty L, Weiss G, Logan T . Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2004; 23(1):133-41. DOI: 10.1200/JCO.2005.03.206. View

Da Silva C, Camps M, Li T, Chan A, Ossendorp F, Cruz L . Co-delivery of immunomodulators in biodegradable nanoparticles improves therapeutic efficacy of cancer vaccines. Biomaterials. 2019; 220:119417. DOI: 10.1016/j.biomaterials.2019.119417. View

Lu J, Wang X, Marin-Muller C, Wang H, Lin P, Yao Q . Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn. 2009; 9(4):325-41. PMC: 2701163. DOI: 10.1586/erm.09.15. View

Zheng Y, Tang L, Mabardi L, Kumari S, Irvine D . Enhancing Adoptive Cell Therapy of Cancer through Targeted Delivery of Small-Molecule Immunomodulators to Internalizing or Noninternalizing Receptors. ACS Nano. 2017; 11(3):3089-3100. PMC: 5647839. DOI: 10.1021/acsnano.7b00078. View

Chen P, Pan W, Wu C, Yeh C, Korupalli C, Luo P . Modulation of tumor microenvironment using a TLR-7/8 agonist-loaded nanoparticle system that exerts low-temperature hyperthermia and immunotherapy for in situ cancer vaccination. Biomaterials. 2019; 230:119629. DOI: 10.1016/j.biomaterials.2019.119629. View

Acharya S, Sahoo S . PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev. 2010; 63(3):170-83. DOI: 10.1016/j.addr.2010.10.008. View

Chen Q, Wang C, Zhang X, Chen G, Hu Q, Li H . In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment. Nat Nanotechnol. 2018; 14(1):89-97. DOI: 10.1038/s41565-018-0319-4. View

10.

Xu Q, Guo L, Gu X, Zhang B, Hu X, Zhang J . Prevention of colorectal cancer liver metastasis by exploiting liver immunity via chitosan-TPP/nanoparticles formulated with IL-12. Biomaterials. 2012; 33(15):3909-18. DOI: 10.1016/j.biomaterials.2012.02.014. View

11.

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

12.

Donatan S, Yashchenok A, Khan N, Parakhonskiy B, Cocquyt M, Pinchasik B . Loading Capacity versus Enzyme Activity in Anisotropic and Spherical Calcium Carbonate Microparticles. ACS Appl Mater Interfaces. 2016; 8(22):14284-92. DOI: 10.1021/acsami.6b03492. View

13.

Curnis F, Fiocchi M, Sacchi A, Gori A, Gasparri A, Corti A . NGR-tagged nano-gold: A new CD13-selective carrier for cytokine delivery to tumors. Nano Res. 2016; 9(5):1393-1408. PMC: 4876925. DOI: 10.1007/s12274-016-1035-8. View

14.

Mihalik N, Wen S, Driesschaert B, Eubank T . Formulation and In Vitro Characterization of PLGA/PLGA-PEG Nanoparticles Loaded with Murine Granulocyte-Macrophage Colony-Stimulating Factor. AAPS PharmSciTech. 2021; 22(5):191. PMC: 8361900. DOI: 10.1208/s12249-021-02049-z. View

15.

Huo Q, Liu J, Wang L, Jiang Y, Lambert T, Fang E . A new class of silica cross-linked micellar core-shell nanoparticles. J Am Chem Soc. 2006; 128(19):6447-53. DOI: 10.1021/ja060367p. View

16.

Watanabe A, Nishida S, Burcu T, Shibahara T, Kusakabe T, Kuroda E . Safety and immunogenicity of a quadrivalent seasonal influenza vaccine adjuvanted with hydroxypropyl-β-cyclodextrin: A phase 1 clinical trial. Vaccine. 2022; 40(31):4150-4159. DOI: 10.1016/j.vaccine.2022.05.060. View

17.

Chu D, Dong X, Shi X, Zhang C, Wang Z . Neutrophil-Based Drug Delivery Systems. Adv Mater. 2018; 30(22):e1706245. PMC: 6161715. DOI: 10.1002/adma.201706245. View

18.

Malik A, Gupta M, Gupta V, Gogoi H, Bhatnagar R . Novel application of trimethyl chitosan as an adjuvant in vaccine delivery. Int J Nanomedicine. 2018; 13:7959-7970. PMC: 6260144. DOI: 10.2147/IJN.S165876. View

19.

Huang P, Wang X, Liang X, Yang J, Zhang C, Kong D . Nano-, micro-, and macroscale drug delivery systems for cancer immunotherapy. Acta Biomater. 2018; 85:1-26. DOI: 10.1016/j.actbio.2018.12.028. View

20.

Ye H, Tong J, Wu J, Xu X, Wu S, Tan B . Preclinical evaluation of recombinant human IFNα2b-containing magnetoliposomes for treating hepatocellular carcinoma. Int J Nanomedicine. 2014; 9:4533-50. PMC: 4184408. DOI: 10.2147/IJN.S67228. View